以人工智慧为基础的数位病理市场：产业趋势及全球预测（至 2035 年）—依神经网路类型、侦测类型、终端使用者类型、应用领域、目标疾病和主要地区划分

基于人工智慧的数位病理市场—概述

根据 Roots Analysis 的研究，全球基于人工智慧的数位病理市场预计将从目前的 10.1 亿美元增长到 2035 年的 23.2 亿美元，预测期内（至 2035 年）的复合年增长率 (CAGR) 为 8.7%。

神经网路类型

• 人工神经网络
• 卷积神经网络
• 全卷积网络
• 循环神经网络
• 其他

检测类型

• ER 检测
• HER2 检测
• Ki-67、PR 检测
• 其他

最终使用者类型

• 学术机构
• 医院/医疗机构
• 实验室/诊断机构
• 研究机构
• 其他

应用领域

• 诊断
• 研究
• 其他

标靶疾病

• 乳癌
• 大肠直肠癌
• 子宫颈癌
• 胃肠道癌
• 肺癌
• 前列腺癌
• 其他

主要地区

• 北美
• 欧洲
• 亚太地区
• 中东和北非
• 拉丁美洲

基于人工智慧的数位病理市场 - 成长与趋势

近年来，技术的进步和对精准医疗日益增长的关注推动了人工智慧 (AI) 的发展，并促进了用于样本定量和定性评估的数位病理技术的应用。这项技术进步使得透过电脑显示来检查切片成为可能，取代了传统的显微镜方法。此外，将玻璃切片转换为影像显着加快了样本从诊断中心到病理学家的转移速度。尤其值得注意的是，人工智慧的整合显着加深了对组织微环境的理解。人工智慧在诊断中的应用使得确定针对每位患者个体情况的最佳治疗策略成为可能，并且数位化方法正被用于对患者进行分类，筛选出符合诊断评估条件的患者。

鑑于病理学领域产生的数据量庞大，人工智慧有望为病理学所有子领域的创新提供机遇，并在影像和非影像诊断领域实现变革性的医疗服务模式。由于其优于传统病理学方法的优势，基于人工智慧的数位病理学领域近年来经历了显着增长，这些解决方案在研究、开发和临床环境中变得越来越普遍。

基于人工智慧的数位病理学市场—主要发现

本报告深入分析了基于人工智慧的数位病理学市场的现状，并指出了该行业潜在的成长机会。报告的主要发现包括：

• 目前，约有 80 家公司声称向多个地理位置分散的终端用户提供基于人工智慧的数位病理服务。

• 利害关係人正在利用其专业知识提供各种基于人工智慧的病理服务，这些解决方案主要被研究机构和诊断实验室采用。
• 该领域的公司透过针对研究和诊断应用的专有产品提供一系列功能。
• 投资人意识到该领域的商机，已透过 60 轮融资累计投资约 20 亿美元。

• 包括调查部署和人工智慧在临床工作流程中的整合在内的多种因素，正在推动全球范围内基于人工智慧的数位病理工具的普及。

• 在对基于人工智慧的数位病理解决方案的需求不断增长以及对更便捷的医疗保健服务日益增长的偏好推动下，预计到2035年，该市场将以每年8.70%的速度增长。

基于人工智慧的数位病理市场 - 主要区隔市场

预计在预测期内，卷积神经网路将主导基于人工智慧的数位病理市场。

此市场依神经网路类型区隔为人工神经网路、卷积神经网路、全捲积网路、循环神经网路和其他神经网路。卷积神经网路在基于人工智慧的数位病理市场中占最大占有率。值得注意的是，基于人工智慧的神经网路数位病理市场预计将以更高的复合年增长率成长。

目前，Ki67 检测在基于人工智慧的数位病理市场中占最大占有率。

依检测类型划分，市场可分为 ER 检测、HER2 检测、Ki67 检测、PR 检测和其他检测。 Ki67 检测占了基于人工智慧的数位病理市场的大部分占有率。这是因为 Ki67 表达与细胞增殖密切相关，并且经常被用作增殖标誌物，用于在常规病理检测中量化人类恶性肿瘤的细胞增殖率。

目前，研究机构在基于人工智慧的数位病理市场中占最大占有率。

依最终使用者类型划分，市场区隔包括学术机构、医院/医疗机构、检测/诊断机构、研究机构和其他最终使用者。目前，研究机构在人工智慧数位病理市场中占最大占有率，预计未来几年这一趋势将保持不变。

在预测期内，诊断领域将成为人工智慧数位病理市场中成长最快的领域。

依应用领域划分，该市场可分为诊断、研究和其他应用。值得注意的是，研究领域目前在人工智慧数位病理市场中占有较大占有率。然而，诊断领域预计将以更高的复合年增长率成长。

预计在预测期内，乳癌将成为推动人工智慧数位病理市场成长的主要因素。

依目标疾病划分，该市场可分为乳癌、大肠癌、子宫颈癌、胃肠道癌、肺癌、摄护腺癌和其他适应症。值得注意的是，乳癌目前占人工智慧数位病理市场的大部分占有率。预计这一趋势将在未来十年持续。

北美将占最大的市场占有率。

依主要地区划分，市场分为北美、欧洲、亚太、拉丁美洲、中东和北非以及世界其他地区。总部位于北美的公司预计将占大部分市场占有率。值得注意的是，预计未来几年欧洲市场的复合年增长率将更高。

人工智慧数位病理市场代表性公司

• Aiforia Technologies
• Akoya Biosciences
• Ibex Medical Analytics
• Indica Labs
• Paige
• PathAI
• PROSCIA
• Roche Tissue Diagnostics
• Visiopharm

主要研究概述

本研究提出的观点和见解是基于与多位利害关係人的讨论。本报告包​​含对以下行业专业人士的详细访谈：

• A公司董事长兼首席执行官
• B公司实验室主任兼首席病理学家
• C公司副总裁（研发与科技）
• D公司销售与行销副总裁

基于人工智慧的数位病理市场 - 研究范围

• 市场规模和机会分析：本报告对基于人工智慧的数位病理市场进行了详细分析，重点关注以下关键市场区隔：[A] 神经网路类型，[B] 检测类型，[C] 终端用户类型，[D] 应用领域，[E] 目标疾病，以及 [F] 主要地区。
• 市场概况：对基于人工智慧的数位病理公司进行全面评估，评估内容包括：[A] 地理覆盖范围，[B] 成立年份，[C] 公司规模（员工人数），[D] 总部所在地，[E] 产品类型，[F] 服务类型，[G] 终端功能类型，[H] 附加功能，[E] 应用疾病可用软体数量。
• 主要发现：深入分析，重点阐述当前市场趋势，包括：[A] 依服务类型和应用领域划分的分布，[B] 依功能类型和应用领域划分的分布，[C] 依产品类型和应用领域划分的分布，[D] 依产品类型和总部所在地划分的分布，以及基于 [E] 公司规模和 [F] 总部的基于分析人工智慧的数位病理公司的综合公司所在地的综合分析。
• 公司简介：提供基于人工智慧的数位病理服务主要公司的详细简介，重点关注[A]公司概况、[B]近期发展和[C]未来展望。
• 公司竞争分析：对基于人工智慧的数位病理公司进行全面的竞争分析。我们考察了投资组合实力和融资活动等因素。
• 融资与投资分析：我们基于相关参数对数位病理市场的投资进行详细评估，例如[A]投资案例数、[B]投资金额、[C]融资类型、[D]应用领域、[E]地区和[F]基于人工智慧的数位病理领域最活跃的企业。
• 需求分析：我们基于相关参数估算基于人工智慧的数位病理的年度需求，例如[A]地区（北美、欧洲、亚洲、拉丁美洲、中东和北非以及世界其他地区）和[B]最终用户（医院、研究机构和其他最终用户）。

目录

第一章：引言

第二章：摘要整理

第三章：导论

• 章节概述
• 人工智慧在数位病理学的应用
• 基于人工智慧的数位病理学工作流程
• 基于人工智慧的数位病理学解决方案的应用
• 针对基于人工智慧的数位病理学的监管要求
• 人工智慧在数位病理学应用中面临的挑战
• 未来展望

第四章：基于人工智慧的数位病理学：市场概况

• 章节概述
• 基于人工智慧的数位病理学提供者：开发者视角
• 基于人工智慧的数位病理学提供者：市场概况

第五章：基于人工智慧的数位病理学市场 - 主要洞察

第六章：公司简介

• 章节概述
• PathAI
• Paige
• Akoya Biosciences
• PROSCIA
• Visiopharm
• Roche Tissue Diagnostics
• Aiforia Technologies
• Indica Labs
• Ibex Medical Analytics

第七章：竞争分析

第八章：融资与投资

• 章节概述
• 融资类型
• 基于人工智慧的数位病理学：融资与投资列表
• 结论

第九章：需求分析

• 章节概述
• 研究范围与方法
• 2035 年前全球对基于人工智慧的数位病理学的需求
• 基于人工智慧的数位病理学需求：区域分析
  • 北美地区对基于人工智慧的数位病理学的需求
  • 欧洲地区对基于人工智慧的数位病理学的需求
  • 亚洲地区对以人工智慧为基础的数位病理学的需求
  • 拉丁美洲地区对基于人工智慧的数位病理学的需求
  • 中东和北非地区对基于人工智慧的数位病理学的需求
  • 世界其他地区对基于人工智慧的数位病理学的需求
• 基于人工智慧的数位病理学需求：依最终用户类型分析
  • 医院对基于人工智慧的数位病理学的需求
  • 科学研究机构对以人工智慧为基础的数位病理学的需求机构
  • 全球其他地区对基于人工智慧的数位病理学的需求
• 结论

第十章 市场规模评估与机会分析

• 章节概述
• 预测研究方法与关键假设
• 全球基于人工智慧的数位病理学市场至2035年
• 基于人工智慧的数位病理学市场 - 依神经网路类型划分的分析（当前及2035年）
• 基于人工智慧的数位病理学市场 - 依检测类型划分的分析（当前及2035年）
• 基于人工智慧的数位病理学市场 - 依最终用户类型划分的分析（当前及2035年）
• 基于人工智慧的数位病理学市场 - 依应用领域划分的分析（当前及2035年）
• 基于人工智慧的数位病理学市场 - 依目标疾病划分的分析（当前及2035年）
• 以人工智慧为基础的数位病理学市场－主要地区分析（现况及2035年展望）

第十一章：结论

第十二章：高阶主管洞察

第十三章：附录一：表格资料

第十四章：附录二：公司及机构名单

AI-based Digital Pathology Market: Overview

As per Roots Analysis, the global AI-based digital pathology market is estimated to grow from USD 1.01 billion in the current year to USD 2.32 billion by 2035, at a CAGR of 8.7% during the forecast period, till 2035.

Type of Neural Network

• Artificial Neural Network
• Convolutional Neural Network
• Fully Convolutional Network,
• Recurrent Neural Network
• Other Neural Network

Type of Assay

• ER Assay
• HER2 Assay
• KI67, PR Assay
• Other Type of Assay

Type of End-User

• Academic Institutions
• Hospitals / Healthcare Institutions
• Laboratories / Diagnostic Institutions
• Research Institutes
• Other End-Users

Area of Application

• Diagnostics
• Research
• Other Areas of Application

Target Disease Indication

• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Gastrointestinal Cancer
• Lung Cancer
• Prostate Cancer
• Other Indications

Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and North Africa
• Latin America

AI-based Digital Pathology Market: Growth and Trends

In recent years, advancements in technology and an emphasis on precision medicine have paved the way for the development of artificial intelligence (AI), which has spurred digital pathology techniques for both quantitative and qualitative assessment of samples. The improved technique allows for the examination of slides via computer displays, replacing conventional microscopic approaches. Additionally, converting glass slides into images allows for samples to be transmitted from diagnostic centers to pathologists much more quickly. It is essential to highlight that the integration of AI has significantly enhanced the understanding of tissue micro-environment. AI involvement in diagnosis enables the determination of optimal treatment strategies suited to patient profiles, utilizing digital methods for categorizing patients and selecting individuals for diagnostic evaluations.

Given the vast amount of data generated in pathology, AI is expected to offer an opportunity for innovation across all pathology subdomains, enabling a transformative model for care delivery in both imaging and non-imaging areas. As a result of the aforementioned advantages over conventional techniques in pathology, the AI-based digital pathology sector has seen significant growth in recent times, with these solutions becoming increasingly popular in research, development, and clinical settings.

AI-based Digital Pathology Market: Key Insights

The report delves into the current state of the AI-based digital pathology market and identifies potential growth opportunities within the industry. Some key findings from the report include:

• Presently, close to 80 players claim to provide AI-based digital pathology services to multiple end-users located across different geographical locations.

• Leveraging their expertise, stakeholders are offering a range of AI-based services for pathology applications; such solutions are primarily being employed by research institutes and laboratory / diagnostic institutions.
• Companies engaged in this domain are offering a range of features through their proprietary products, intended for both research and diagnostic applications.
• Having realized the opportunity associated with this segment, investors have collectively invested ~USD 2 billion, across 60 funding instances.

• A number of factors, such as inclusion of research, as well as the incorporation of AI in the clinical workflow, have led to a rise in the adoption of AI-based digital pathology tools, on a global scale.

• Driven by the rise in demand for AI-based digital pathology solutions and the growing preference for more accessible healthcare services, this market is anticipated to grow at an annualized rate of 8.70% till 2035.

AI-based Digital Pathology Market: Key Segments

Convolutional Neural Network is Likely to Dominate the AI-based Digital Pathology Market During the Forecast Period

In terms of the type of neural network, the market is segmented into artificial neural network, convolutional neural network, fully convolutional network, recurrent neural network and other neural network. The maximum share of the AI-based digital pathology market is captured by convolutional neural network. It is worth highlighting that the AI-based digital pathology market for artificial neural networks is likely to grow at a higher CAGR.

Currently, Ki67 Assays Occupy the Largest Share of the AI-based Digital Pathology Market

In terms of type of assay, the market is segmented into ER assay, HER2 assay, Ki67 assay, PR assay and other type of assay. The majority of the AI-based digital pathology market share is captured by Ki67 assay. This is due to the fact that the expression of Ki67 assays is highly related to cell proliferation and hence, is frequently employed in routine pathology, as a proliferation marker to quantify the growth fraction of cells in human malignancies.

Currently, Research Institutes Occupy the Largest Share of the AI-based Digital Pathology Market

In terms of type of end-user, the market is segmented into academic institutions, hospitals/ healthcare institutions, laboratories / diagnostic institutions, research institutes and other end-users. Currently, research institutes hold the maximum share of the AI-based digital pathology market and the trend will be similar in the coming years.

Diagnostics Segment is the Fastest Growing Segment of the AI-based Digital Pathology Market During the Forecast Period

In terms of area of application, the market is segmented into diagnostics, research and other areas of application. It is worth highlighting that, at present, the research segment holds a larger share of the AI-based digital pathology market. However, the AI-based digital pathology market for diagnostics is likely to grow at a higher CAGR.

Breast Cancer is Likely to Dominate the AI-based Digital Pathology Market During the Forecast Period

In terms of the target disease indication, the market is segmented into breast cancer, colorectal cancer, cervical cancer, gastrointestinal cancer, lung cancer, prostate cancer and other indications. It is worth highlighting that majority of the current AI-based digital pathology market is captured by breast cancer. This trend is likely to remain the same in the coming decade.

North America Accounts for the Largest Share of the Market

In terms of key geographical regions, the market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and the Rest of the World. The majority of the share is expected to be captured by players based in North America. It is worth highlighting that, over the years, the market in Europe is expected to grow at a higher CAGR.

Example Players in the AI-based Digital Pathology Market

• Aiforia Technologies
• Akoya Biosciences
• Ibex Medical Analytics
• Indica Labs
• Paige
• PathAI
• PROSCIA
• Roche Tissue Diagnostics
• Visiopharm

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Chief Executive Officer and Chairman, Company A
• Laboratory Director and Chief Pathologist, Company B
• Vice President (Research and Technology), Company C
• Vice President (Sales and Marketing), Company D

AI-based Digital Pathology Market: Research Coverage

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the AI-based digital pathology market, focusing on key market segments, including [A] type of neural network, [B] type of assay, [C] type of end-user, [D] area of application, [E] target disease indication and [F] key geographical regions.
• Market Landscape: A comprehensive evaluation of AI-based digital pathology companies, considering various parameters, such as [A] geographical reach, [B] year of establishment, [C] company size (in terms of number of employees), [D] location of headquarters, [E] type of product, [F] type of service, [G] type of feature, [H] additional features, [I] area of application, [J] target disease indication, [K] type of assay, [L] type of end-user and [M] information on number of available software.
• Key Insights: An in-depth analysis, highlighting the contemporary market trends, including [A] distribution based on type of service and area of application, [B] distribution based on type of feature and area of application, [C] distribution based on type of product and area of application, [D] type of product and location of headquarters, as well as an insightful hybrid representation of AI-based digital pathology companies based on [E] company size and [F] location of headquarters.
• Company Profiles: In-depth profiles of key AI-based digital pathology companies offering AI-based digital pathology services, focusing on [A] company overviews, [B] recent developments and [C] an informed future outlook.
• Company Competitiveness Analysis: A comprehensive competitive analysis of AI-based digital pathology companies, examining factors, such as portfolio strength and funding activity.
• Funding and Investment Analysis: A detailed evaluation of the investments made in digital pathology market based on several relevant parameters, such as [A] number of instances, [B] amount invested, [C] type of funding, [D] area of application, [E] geography and [F] most active players engaged in the AI-based digital pathology domain.
• Demand Analysis: Informed estimates of the annual demand for AI-based digital pathology based on several relevant parameters, such as [A] geography (North America, Europe, Asia, Latin America, MENA and Rest of the World) and [B] end-users (hospitals, research and other end-users).

Key Questions Answered in this Report

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Chapter Overview
• 1.2. Market Segmentations
• 1.3. Research Methodology
• 1.4. Key Questions Answered
• 1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Chapter Overview
• 3.2. Artificial Intelligence in Digital Pathology
• 3.3. Workflow of AI-based Digital Pathology
• 3.4. Applications of AI-based Digital Pathology Solutions
• 3.5. Regulatory Requirements Focused on AI-based Digital Pathology:
• 3.6. Challenges Associated with the Use of AI in Digital Pathology
• 3.7. Future Perspectives

4. AI-BASED DIGITAL PATHOLOGY: MARKET LANDSCAPE

• 4.1. Chapter Overview
• 4.2. AI-based Digital Pathology Providers: Developers Landscape
  • 4.2.1. Analysis by Year of Establishment
  • 4.2.2. Analysis by Company Size
  • 4.2.3. Analysis by Location of Headquarters
  • 4.2.4. Analysis by Geographical Reach
• 4.3. AI-based Digital Pathology Providers: Market Landscape
  • 4.3.1. Analysis by Type of Product
  • 4.3.2. Analysis by Type of Service Offered
  • 4.3.3. Analysis by Type of Feature
  • 4.3.4. Analysis by Additional Features
  • 4.3.5. Analysis by Target Disease Indication
  • 4.3.6. Analysis by Type of Assay
  • 4.3.7. Analysis by Area of Application
  • 4.3.8. Analysis by Type of End-user
  • 4.3.9. Analysis by Number of Available Software

5. AI-BASED DIGITAL PATHOLOGY MARKET: KEY INSIGHTS

• 5.1. Chapter Overview
  • 5.1.1. Analysis by Type of Service and Area of Application
  • 5.1.2. Analysis by Type of Feature and Area of Application
  • 5.1.3. Analysis by Type of Product and Area of Application
  • 5.1.4. Analysis by Type of Product and Location of Headquarters
  • 5.1.5. Analysis by Company Size and Location of Headquarters

6. COMPANY PROFILES

• 6.1. Chapter Overview
• 6.2. PathAI
  • 6.2.1. Company Overview
  • 6.2.2. Recent Developments and Future Outlook
• 6.3. Paige
  • 6.3.1. Company Overview
  • 6.3.2. Recent Developments and Future Outlook
• 6.4. Akoya Biosciences
  • 6.4.1. Company Overview
  • 6.4.2. Recent Developments and Future Outlook
• 6.5. PROSCIA
  • 6.5.1. Company Overview
  • 6.5.2. Recent Developments and Future Outlook
• 6.6. Visiopharm
  • 6.6.1. Company Overview
  • 6.6.2. Recent Developments and Future Outlook
• 6.7. Roche Tissue Diagnostics
  • 6.7.1. Company Overview
  • 6.7.2. Recent Developments and Future Outlook
• 6.8. Aiforia Technologies
  • 6.8.1. Company Overview
  • 6.8.2. Recent Developments and Future Outlook
• 6.9. Indica Labs
  • 6.9.1. Company Overview
  • 6.9.2. Recent Developments and Future Outlook
• 6.10. Ibex Medical Analytics
  • 6.10.1. Company Overview
  • 6.10.2. Recent Developments and Future Outlook

7. COMPANY COMPETITIVENESS ANALYSIS

• 7.1. Chapter Overview
• 7.2. Assumptions and Key Parameters
• 7.3. Methodology
• 7.4. Benchmarking of Portfolio Strength
• 7.5. Benchmarking of Funding Strength
• 7.6. Company Competitiveness Analysis: Small Players
• 7.7. Company Competitiveness Analysis: Mid-sized Players
• 7.8. Company Competitiveness Analysis: Large Players

8. FUNDING AND INVESTMENTS

• 8.1. Chapter Overview
• 8.2. Types of Funding
• 8.3. AI-based Digital Pathology: List of Funding and Investments
  • 8.3.1. Cumulative Year-wise Trend by Number of Instances
  • 8.3.2. Cumulative Year-wise Trend by Amount Invested
  • 8.3.3. Analysis by Type of Funding
  • 8.3.4. Analysis by Type of Funding and Amount Invested
  • 8.3.5. Analysis by Area of Application
  • 8.3.6. Analysis by Type of Funding and Area of Application
  • 8.3.7. Analysis by Geography
  • 8.3.8. Most Active Players: Analysis by Number of Funding Instances
  • 8.3.9. Most Active Players: Analysis by Amount Raised
• 8.4. Concluding Remarks

9. DEMAND ANALYSIS

• 9.1. Chapter Overview
• 9.2. Scope and Methodology
• 9.3. Global Demand for AI-based Digital Pathology, till 2035
• 9.4. Demand for AI-based Digital Pathology: Analysis by Geography
  • 9.4.1. Demand for AI-based Digital Pathology in North America
    • 9.4.1.1 Demand for AI-based Digital Pathology in the US
    • 9.4.1.2 Demand for AI-based Digital Pathology in Canada
  • 9.4.2. Demand for AI-based Digital Pathology in Europe
    • 9.4.2.1. Demand for AI-based Digital Pathology in UK
    • 9.4.2.2. Demand for AI-based Digital Pathology in Germany
    • 9.4.2.3. Demand for AI-based Digital Pathology in Spain
    • 9.4.2.4. Demand for AI-based Digital Pathology in Italy
    • 9.4.2.5. Demand for AI-based Digital Pathology in France
  • 9.4.3. Demand for AI-based Digital Pathology in Asia
    • 9.4.3.1. Demand for AI-based Digital Pathology in China
    • 9.4.3.2. Demand for AI-based Digital Pathology in Japan
    • 9.4.3.3. Demand for AI-based Digital Pathology in South Korea
  • 9.4.4. Demand for AI-based Digital Pathology in Latin America
    • 9.4.4.1. Demand for AI-based Digital Pathology in Brazil
  • 9.4.5. Demand for AI-based Digital Pathology in MENA
    • 9.4.5.1. Demand for AI-based Digital Pathology in Saudi Arabia
  • 9.4.6. Demand for AI-based Digital Pathology in Rest of the World
    • 9.4.6.1. Demand for AI-based Digital Pathology in Australia
• 9.5. Demand for AI-based Digital Pathology: Analysis by Type of End-user
  • 9.5.1 Demand for AI-based Digital Pathology in Hospitals
  • 9.5.2. Demand for AI-based Digital Pathology in Research Institutes
  • 9.5.3. Demand for AI-based Digital Pathology in Other End-users
• 9.6. Concluding Remarks

10. MARKET SIZING AND OPPORTUNITY ANALYSIS

• 10.1. Chapter Overview
• 10.2. Forecast Methodology and Key Assumptions
• 10.3. Global AI-based Digital Pathology Market, till 2035
• 10.4. AI-based Digital Pathology Market: Analysis by Type of Neural Network, Current Year and 2035
  • 10.4.1. AI-based Digital Pathology Market for Artificial Neural Network, till 2035
  • 10.4.2. AI-based Digital Pathology Market for Convolutional Neural Network, till 2035
  • 10.4.3. AI-based Digital Pathology Market for Fully Convolutional Network, till 2035
  • 10.4.4. AI-based Digital Pathology Market for Recurrent Neural Network, till 2035
  • 10.4.5. AI-based Digital Pathology Market for Other Neural Networks, till 2035
• 10.5. AI-based Digital Pathology Market: Analysis by Type of Assay, Current Year and 2035
  • 10.5.1. AI-based Digital Pathology Market for ER Assay, till 2035
  • 10.5.2. AI-based Digital Pathology Market for HER2 Assay, till 2035
  • 10.5.3. AI-based Digital Pathology Market for Ki67 Assay, till 2035
  • 10.5.4. AI-based Digital Pathology Market for PD-L1 Assay, till 2035
  • 10.5.5. AI-based Digital Pathology Market for PR Assay, till 2035
  • 10.5.6. AI-based Digital Pathology Market for Other Type of Assays, till 2035
• 10.6. AI-based Digital Pathology Market: Analysis by Type of End-user, Current Year and 2035
  • 10.6.1. AI-based Digital Pathology Market for Academic Institutions, till 2035
  • 10.6.2. AI-based Digital Pathology Market for Hospitals / Healthcare Institutions, till 2035
  • 10.6.3. AI-based Digital Pathology Market for Laboratories / Diagnostic Institutions, till 2035
  • 10.6.4. AI-based Digital Pathology Market for Research Institutes, till 2035
  • 10.6.5. AI-based Digital Pathology Market for Other End-users, till 2035
• 10.7. AI-based Digital Pathology Market: Analysis by Area of Application, Current Year and 2035
  • 10.7.1. AI-based Digital Pathology Market for Diagnostics, till 2035
  • 10.7.2. AI-based Digital Pathology Market for Research, till 2035
  • 10.7.3. AI-based Digital Pathology Market for Other Areas of Application, till 2035
• 10.8. AI-based Digital Pathology Market: Analysis by Target Disease Indication, Current Year and 2035
  • 10.8.1. AI-based Digital Pathology Market for Breast Cancer, till 2035
  • 10.8.2. AI-based Digital Pathology Market for Colorectal Cancer, till 2035
  • 10.8.3. AI-based Digital Pathology Market for Cervical Cancer, till 2035
  • 10.8.4. AI-based Digital Pathology Market for Gastrointestinal Cancer, till 2035
  • 10.8.5. AI-based Digital Pathology Market for Lung Cancer, till 2035
  • 10.8.6. AI-based Digital Pathology Market for Prostate Cancer, till 2035
  • 10.8.7. AI-based Digital Pathology Market for Other Indications, till 2035
• 10.9. AI-based Digital Pathology Market: Analysis by Key Geographies, Current Year and 2035
  • 10.9.1. AI-based Digital Pathology Market in North America, till 2035
    • 10.9.1.1. AI-based Digital Pathology Market in the US, till 2035
    • 10.9.1.2. AI-based Digital Pathology Market in Canada, till 2035
  • 10.9.2. AI-based Digital Pathology Market in Europe, till 2035
    • 10.9.2.1. AI-based Digital Pathology Market in UK, till 2035
    • 10.9.2.2. AI-based Digital Pathology Market in Germany, till 2035
    • 10.9.2.3. AI-based Digital Pathology Market in Spain, till 2035
    • 10.9.2.4. AI-based Digital Pathology Market in Italy, till 2035
    • 10.9.2.5. AI-based Digital Pathology Market in France, till 2035
  • 10.9.3. AI-based Digital Pathology Market in Asia, till 2035
    • 10.9.3.1. AI-based Digital Pathology Market in China, till 2035
    • 10.9.3.2. AI-based Digital Pathology Market in Japan, till 2035
    • 10.9.3.3. AI-based Digital Pathology Market in South Korea, till 2035
  • 10.9.4. AI-based Digital Pathology Market in Latin America, till 2035
    • 10.9.4.1. AI-based Digital Pathology Market in Brazil, till 2035
  • 10.9.5. AI-based Digital Pathology Market in MENA, till 2035
    • 10.9.5.1. AI-based Digital Pathology Market in Saudi Arabia, till 2035
  • 10.9.6. AI-based Digital Pathology Market in Rest of the World, till 2035
    • 10.9.6.1. AI-based Digital Pathology Market in Australia, till 2035

11. CONCLUDING REMARKS

12. EXECUTIVE INSIGHTS

• 12.1. Chapter Overview
• 12.2. Company A
  • 12.2.1. Company Snapshot
  • 12.2.2. Interview Transcript: Chief Executive Officer and Chairman
• 12.3. Company B
  • 12.3.1. Company Snapshot
  • 12.3.2. Interview Transcript: Laboratory Director and Chief Pathologist
• 12.4. Company C
  • 12.4.1. Company Snapshot
  • 12.4.2. Interview Transcript: Vice President, Research and Technology
• 12.5. Company D
  • 12.5.1. Company Snapshot
  • 12.5.2. Interview Transcript: Vice President, Sales and Marketing
• 12.6. Company E
  • 12.6.1. Company Snapshot
  • 12.6.2. Interview Transcript: Vice President, Business Development and Strategic Partnerships

13. APPENDIX 1: TABULATED DATA

14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION

List of Tables

• Table 4.1 List of AI-based Digital Pathology Providers
• Table 4.2 AI-based Digital Pathology Providers: Information on Type of Product
• Table 4.3 AI-based Digital Pathology Providers: Information on Type of Service Offered
• Table 4.4 AI-based Digital Pathology Providers: Information on Type of Feature
• Table 4.5 AI-based Digital Pathology Providers: Information on Additional Features
• Table 4.6 AI-based Digital Pathology Providers: Information on Target Disease Indication
• Table 4.7 AI-based Digital Pathology Providers: Information on Type of Assay
• Table 4.8 AI-based Digital Pathology Providers: Information on Area of Application
• Table 4.9 AI-based Digital Pathology Providers: Information on Type of End-user
• Table 6.1 AI-based Digital Pathology Providers: List of Profiled Companies
• Table 6.2 PathAI: Company Snapshot
• Table 6.3 PathAI: Recent Developments and Future Outlook
• Table 6.4 Paige: Company Snapshot
• Table 6.5 Paige: Recent Developments and Future Outlook
• Table 6.6 Akoya Biosciences: Company Snapshot
• Table 6.7 Akoya Biosciences: Recent Developments and Future Outlook
• Table 6.8 PROSCIA: Company Snapshot
• Table 6.9 PROSCIA: Recent Developments and Future Outlook
• Table 6.10 Visiopharm: Company Snapshot
• Table 6.11 Visiopharm: Recent Developments and Future Outlook
• Table 6.12 Roche Tissue Diagnostics: Company Snapshot
• Table 6.13 Roche Tissue Diagnostics: Recent Developments and Future Outlook
• Table 6.14 Aiforia Technologies: Company Snapshot
• Table 6.15 Aiforia Technologies: Recent Developments and Future Outlook
• Table 6.16 Indica Labs: Company Snapshot
• Table 6.17 Indica Labs: Recent Developments and Future Outlook
• Table 6.18 Ibex Medical Analytics: Company Snapshot
• Table 6.19 Ibex Medical Analytics: Recent Developments and Future Outlook
• Table 8.1 AI-based Digital Pathology Providers: List of Funding and Investments
• Table 12.1 aetherAI: Company Snapshot
• Table 12.2 Clinitech Laboratory: Company Snapshot
• Table 12.3 Huron Digital Pathology: Company Snapshot
• Table 12.4 Mindpeak: Company Snapshot
• Table 12.5 Pramana: Company Snapshot
• Table 13.1 AI-based Digital Pathology Providers: Distribution by Type of Product
• Table 13.2 AI-based Digital Pathology Providers: Distribution by Type of Service Offered
• Table 13.3 AI-based Digital Pathology Providers: Distribution by Type of Feature
• Table 13.4 AI-based Digital Pathology Providers: Distribution by Additional Features
• Table 13.5 AI-based Digital Pathology Providers: Distribution by Target Disease Indication
• Table 13.6 AI-based Digital Pathology Providers: Distribution by Type of Assay
• Table 13.7 AI-based Digital Pathology Providers: Distribution by Area of Application
• Table 13.8 AI-based Digital Pathology Providers: Distribution by Type of End-User
• Table 13.9 AI-based Digital Pathology Providers: Distribution by Number of Available Software
• Table 13.10 AI-based Digital Pathology Providers: Distribution by Geographical Reach
• Table 13.11 AI-based Digital Pathology Providers: Distribution by Year of Establishment
• Table 13.12 AI-based Digital Pathology Providers: Distribution by Company Size
• Table 13.13 AI-based Digital Pathology Providers: Distribution by Location of Headquarters (Country-wise)
• Table 13.14 AI-based Digital Pathology Providers: Distribution by Location of Headquarters (Continent-wise)
• Table 13.15 Key Insights: Distribution by Type of Service and Area of Application
• Table 13.16 Key Insights: Distribution by Type of Feature and Area of Application
• Table 13.17 Key Insights: Distribution by Type of Product and Area of Application
• Table 13.18 Key Insights: Distribution by Type of Product and Location of Headquarters
• Table 13.19 Key Insights: Distribution by Company Size and Location of Headquarters
• Table 13.20 Funding and Investments: Cumulative Year-wise Trend by Number of Instances
• Table 13.21 Funding and Investments: Cumulative Year-wise Trend by Amount Invested
• Table 13.22 Funding and Investments: Distribution of Instances by Type of Funding
• Table 13.23 Funding and Investments: Distribution of Instances by Type of Funding and Amount Invested
• Table 13.24 Funding and Investments: Distribution of Instances by Area of Application
• Table 13.25 Funding and Investments: Distribution of Instances by Geography
• Table 13.26 Most Active Players: Distribution by Number of Funding Instances
• Table 13.27 Most Active Players: Distribution by Amount Raised
• Table 13.28 Funding and Investments: Concluding Remarks
• Table 13.29 Global Demand for AI-based Digital Pathology, till 2035 (Million Slides)
• Table 13.30 Demand for AI-based Digital Pathology: Distribution by Geography, Current Year and 2035
• Table 13.31 Demand for AI-based Digital Pathology in North America, till 2035 (Million Slides)
• Table 13.32 Demand for AI-based Digital Pathology in the US, till 2035 (Million Slides)
• Table 13.33 Demand for AI-based Digital Pathology in Canada, till 2035 (Million Slides)
• Table 13.34 Demand for AI-based Digital Pathology in Europe, till 2035 (Million Slides)
• Table 13.35 Demand for AI-based Digital Pathology in UK, till 2035 (Million Slides)
• Table 13.36 Demand for AI-based Digital Pathology in Germany, till 2035 (Million Slides)
• Table 13.37 Demand for AI-based Digital Pathology in Spain, till 2035 (Million Slides)
• Table 13.38 Demand for AI-based Digital Pathology in Italy, till 2035 (Million Slides)
• Table 13.39 Demand for AI-based Digital Pathology in France, till 2035 (Million Slides)
• Table 13.40 Demand for AI-based Digital Pathology in Asia, till 2035 (Million Slides)
• Table 13.41 Demand for AI-based Digital Pathology in China, till 2035 (Million Slides)
• Table 13.42 Demand for AI-based Digital Pathology in Japan, till 2035 (Million Slides)
• Table 13.43 Demand for AI-based Digital Pathology in South Korea, till 2035 (Million Slides)
• Table 13.44 Demand for AI-based Digital Pathology in Latin America, till 2035 (Million Slides)
• Table 13.45 Demand for AI-based Digital Pathology in Brazil, till 2035 (Million Slides)
• Table 13.46 Demand for AI-based Digital Pathology in MENA, till 2035 (Million Slides)
• Table 13.47 Demand for AI-based Digital Pathology in Saudi Arabia, till 2035 (Million Slides)
• Table 13.48 Demand for AI-based Digital Pathology in Rest of the World, till 2035 (Million Slides)
• Table 13.49 Demand for AI-based Digital Pathology in Australia, till 2035 (Million Slides)
• Table 13.50 Global Demand for AI-based Digital Pathology: Distribution by End-users, Current Year and 2035
• Table 13.51 Global Demand for AI-based Digital Pathology in Hospitals, till 2035 (Million Slides)
• Table 13.52 Global Demand for AI-based Digital Pathology in Research Institutes, till 2035 (Million Slides)
• Table 13.53 Global Demand for AI-based Digital Pathology in Other End-users, till 2035 (Million Slides)
• Table 13.54 Global AI-based Digital Pathology Market, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.55 AI-based Digital Pathology Market: Distribution by Type of Neural Network, Current Year and 2035
• Table 13.56 AI-based Digital Pathology Market for Artificial Neural Network, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.57 AI-based Digital Pathology Market for Convolutional Neural Network, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.58 AI-based Digital Pathology Market for Fully Convolutional Network, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.59 AI-based Digital Pathology Market for Recurrent Neural Network, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.60 AI-based Digital Pathology Market for Other Neural Networks, till 2035, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.61 AI-based Digital Pathology Market: Distribution by Type of Assay, Current Year and 2035
• Table 13.62 AI-based Digital Pathology Market for ER Assay, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.63 AI-based Digital Pathology Market for HER2 Assay, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.64 AI-based Digital Pathology Market for Ki67 Assay, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.65 AI-based Digital Pathology Market for PD-L1 Assay, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.66 AI-based Digital Pathology Market for PR Assay, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.67 AI-based Digital Pathology Market for Other Type of Assays, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.68 AI-based Digital Pathology Market: Distribution by Type of End-user, Current Year and 2035
• Table 13.69 AI-based Digital Pathology Market for Academic Institutions, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.70 AI-based Digital Pathology Market for Hospitals / Healthcare Institutions, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.71 AI-based Digital Pathology Market for Laboratories / Diagnostic Institutions, Conservative, Base and Optimistic Scenario, till 2035 SD Million)
• Table 13.72 AI-based Digital Pathology Market for Research Institutes, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.73 AI-based Digital Pathology Market for Other End-users, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.74 AI-based Digital Pathology Market: Distribution by Area of Application, Current Year and 2035
• Table 13.75 AI-based Digital Pathology Market for Diagnostics, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.76 AI-based Digital Pathology Market for Research, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.77 AI-based Digital Pathology Market for Other Areas of Application, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.78 AI-based Digital Pathology Market: Distribution by Target Disease Indication, Current Year and 2035
• Table 13.79 AI-based Digital Pathology Market for Breast Cancer, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.80 AI-based Digital Pathology Market for Colorectal Cancer, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.81 AI-based Digital Pathology Market for Cervical Cancer, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.82 AI-based Digital Pathology Market for Gastrointestinal Cancer, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.83 AI-based Digital Pathology Market for Lung Cancer, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.84 AI-based Digital Pathology Market for Prostate Cancer, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.85 AI-based Digital Pathology Market for Other Indications, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.86 AI-based Digital Pathology Market: Distribution by Key Geographies, Current Year and 2035
• Table 13.87 AI-based Digital Pathology Market in North America, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.88 AI-based Digital Pathology Market in the US, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.89 AI-based Digital Pathology Market in Canada, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.90 AI-based Digital Pathology Market in the Europe, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.91 AI-based Digital Pathology Market in UK, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.92 AI-based Digital Pathology Market in the Germany, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.93 AI-based Digital Pathology Market in Spain, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.94 AI-based Digital Pathology Market in Italy, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.95 AI-based Digital Pathology Market in France, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.96 AI-based Digital Pathology Market in Asia, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.97 AI-based Digital Pathology Market in China, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.98 AI-based Digital Pathology Market in Japan, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.99 AI-based Digital Pathology Market in South Korea, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.100 AI-based Digital Pathology Market in Latin America, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.101 AI-based Digital Pathology Market in Brazil, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.102 AI-based Digital Pathology Market in MENA, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.103 AI-based Digital Pathology Market in Saudi Arabia, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.104 AI-based Digital Pathology Market in Rest of the World, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
• Table 13.105 AI-based Digital Pathology Market in Australia, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)

List of Figures

• Figure 2.1 Executive Summary: Market Landscape
• Figure 2.2 Executive Summary: Key Insights
• Figure 2.3 Executive Summary: Funding and Investments
• Figure 2.4 Executive Summary: Demand Analysis
• Figure 2.5 Executive Summary: Market Sizing and Opportunity Analysis
• Figure 3.1 Workflow of AI-based Digital Pathology
• Figure 3.2 Applications of AI-based Digital Pathology Solutions
• Figure 4.1 AI-based Digital Pathology Providers: Distribution by Year of Establishment
• Figure 4.2 AI-based Digital Pathology Providers: Distribution by Company Size
• Figure 4.3 AI-based Digital Pathology Providers: Distribution by Location of Headquarters (Region-wise)
• Figure 4.4 AI-based Digital Pathology Providers: Distribution by Location of Headquarters (Country-wise)
• Figure 4.5 AI-based Digital Pathology Providers: Distribution by Geographical Reach
• Figure 4.6 AI-based Digital Pathology Providers: Distribution by Type of Product
• Figure 4.7 AI-based Digital Pathology Providers: Distribution by Type of Service Offered
• Figure 4.8 AI-based Digital Pathology Providers: Distribution by Type of Feature
• Figure 4.9 AI-based Digital Pathology Providers: Distribution by Additional Features
• Figure 4.10 AI-based Digital Pathology Providers: Distribution by Target Disease Indication
• Figure 4.11 AI-based Digital Pathology Providers: Distribution by Type of Assay
• Figure 4.12 AI-based Digital Pathology Providers: Distribution by Area of Application
• Figure 4.13 AI-based Digital Pathology Providers: Distribution by Type of End-user
• Figure 4.14 AI-based Digital Pathology Providers: Distribution by Number of Available Software
• Figure 5.1 Key Insights: Distribution by Type of Service and Area of Application
• Figure 5.2 Key Insights: Distribution by Type of Feature and Area of Application
• Figure 5.3 Key Insights: Distribution by Type of Product and Area of Application
• Figure 5.4 Key Insights: Distribution by Type of Product and Location of Headquarters
• Figure 5.5 Key Insights: Distribution by Company Size and Location of Headquarters
• Figure 7.1 Company Competitiveness Analysis: Benchmarking of Portfolio Strength
• Figure 7.2 Company Competitiveness Analysis: Benchmarking of Funding Strength
• Figure 7.3 Company Competitiveness Analysis: Small Players
• Figure 7.4 Company Competitiveness Analysis: Mid-sized Players
• Figure 7.5 Company Competitiveness Analysis: Large Players
• Figure 8.1 Funding and Investments: Cumulative Year-wise Trend by Number of Instances
• Figure 8.2 Funding and Investments: Cumulative Year-wise Trend by Amount Invested
• Figure 8.3 Funding and Investments: Distribution of Instances by Type of Funding
• Figure 8.4 Funding and Investments: Distribution of Instances by Type of Funding and Amount Invested
• Figure 8.5 Funding and Investments: Distribution of Instances by Area of Application
• Figure 8.6 Funding and Investments: Distribution of Instances by Geography
• Figure 8.7 Most Active Players: Distribution by Number of Funding Instances
• Figure 8.8 Most Active Players: Distribution by Amount Raised
• Figure 8.9 Funding and Investments: Concluding Remarks
• Figure 9.1 Global Demand for AI-based Digital Pathology, till 2035 (Million Slides)
• Figure 9.2 Demand for AI-based Digital Pathology: Distribution by Geography, Current Year and 2035
• Figure 9.3 Demand for AI-based Digital Pathology in North America, till 2035 (Million Slides)
• Figure 9.4 Demand for AI-based Digital Pathology in the US, till 2035 (Million Slides)
• Figure 9.5 Demand for AI-based Digital Pathology in Canada, till 2035 (Million Slides)
• Figure 9.6 Demand for AI-based Digital Pathology in Europe, till 2035 (Million Slides)
• Figure 9.7 Demand for AI-based Digital Pathology in UK, till 2035 (Million Slides)
• Figure 9.8 Demand for AI-based Digital Pathology in Germany, till 2035 (Million Slides)
• Figure 9.9 Demand for AI-based Digital Pathology in Spain, till 2035 (Million Slides)
• Figure 9.10 Demand for AI-based Digital Pathology in Italy, till 2035 (Million Slides)
• Figure 9.11 Demand for AI-based Digital Pathology in France, till 2035 (Million Slides)
• Figure 9.12 Demand for AI-based Digital Pathology in Asia, till 2035 (Million Slides)
• Figure 9.13 Demand for AI-based Digital Pathology in China, till 2035 (Million Slides)
• Figure 9.14 Demand for AI-based Digital Pathology in Japan, till 2035 (Million Slides)
• Figure 9.15 Demand for AI-based Digital Pathology in South Korea, till 2035 (Million Slides)
• Figure 9.16 Demand for AI-based Digital Pathology in Latin America, till 2035 (Million Slides)
• Figure 9.17 Demand for AI-based Digital Pathology in Brazil, till 2035 (Million Slides)
• Figure 9.18 Demand for AI-based Digital Pathology in MENA, till 2035 (Million Slides)
• Figure 9.19 Demand for AI-based Digital Pathology in Saudi Arabia, till 2035 (Million Slides)
• Figure 9.20 Demand for AI-based Digital Pathology in Rest of the World, till 2035 (Million Slides)
• Figure 9.21 Demand for AI-based Digital Pathology in Australia, till 2035 (Million Slides)
• Figure 9.22 Global Demand for AI-based Digital Pathology: Distribution by Type of End-user, Current Year and 2035
• Figure 9.23 Global Demand for AI-based Digital Pathology in Hospitals, till 2035 (Million Slides)
• Figure 9.24 Global Demand for AI-based Digital Pathology in Research Institutes, till 2035 (Million Slides)
• Figure 9.25 Global Demand for AI-based Digital Pathology in Other End-users, till 2035 (Million Slides)
• Figure 10.1 Global AI-based Digital Pathology Market, till 2035 (USD Million)
• Figure 10.2 AI-based Digital Pathology Market: Distribution by Type of Neural Network, Current Year and 2035
• Figure 10.3 AI-based Digital Pathology Market for Artificial Neural Network, till 2035 (USD Million)
• Figure 10.4 AI-based Digital Pathology Market for Convolutional Neural Network, till 2035 (USD Million)
• Figure 10.5 AI-based Digital Pathology Market for Fully Convolutional Network, till 2035 (USD Million)
• Figure 10.6 AI-based Digital Pathology Market for Recurrent Neural Network, till 2035 (USD Million)
• Figure 10.7 AI-based Digital Pathology Market for Other Neural Networks, till 2035 (USD Million)
• Figure 10.8 AI-based Digital Pathology Market: Distribution by Type of Assay, Current Year and 2035
• Figure 10.9 AI-based Digital Pathology Market for ER Assay, till 2035 (USD Million)
• Figure 10.10 AI-based Digital Pathology Market for HER2 Assay, till 2035 (USD Million)
• Figure 10.11 AI-based Digital Pathology Market for Ki67 Assay, till 2035 (USD Million)
• Figure 10.12 AI-based Digital Pathology Market for PD-L1 Assay, till 2035 (USD Million)
• Figure 10.13 AI-based Digital Pathology Market for PR Assay, till 2035 (USD Million)
• Figure 10.14 AI-based Digital Pathology Market for Other Type of Assays, till 2035 (USD Million)
• Figure 10.15 AI-based Digital Pathology Market: Distribution by Type of End-user, Current Year and 2035
• Figure 10.16 AI-based Digital Pathology Market for Academic Institutions, till 2035 (USD Million)
• Figure 10.17 AI-based Digital Pathology Market for Hospitals / Healthcare Institutions, till 2035 (USD Million)
• Figure 10.18 AI-based Digital Pathology Market for Laboratories / Diagnostic Institutions, till 2035 (USD Million)
• Figure 10.19 AI-based Digital Pathology Market for Research Institutes, till 2035 (USD Million)
• Figure 10.20 AI-based Digital Pathology Market for Other End-users, till 2035 (USD Million)
• Figure 10.21 AI-based Digital Pathology Market: Distribution by Area of Application, Current Year and 2035
• Figure 10.22 AI-based Digital Pathology Market for Diagnostics, till 2035 (USD Million)
• Figure 10.23 AI-based Digital Pathology Market for Research, till 2035 (USD Million)
• Figure 10.24 AI-based Digital Pathology Market for Other Areas of Application, till 2035 (USD Million)
• Figure 10.25 AI-based Digital Pathology Market: Distribution by Target Disease Indication, Current Year and 2035
• Figure 10.26 AI-based Digital Pathology Market for Breast Cancer, till 2035 (USD Million)
• Figure 10.27 AI-based Digital Pathology Market for Colorectal Cancer, till 2035 (USD Million)
• Figure 10.28 AI-based Digital Pathology Market for Cervical Cancer, till 2035 (USD Million)
• Figure 10.29 AI-based Digital Pathology Market for Gastrointestinal Cancer, till 2035 (USD Million)
• Figure 10.30 AI-based Digital Pathology Market for Lung Cancer, till 2035 (USD Million)
• Figure 10.31 AI-based Digital Pathology Market for Prostate Cancer, till 2035 (USD Million)
• Figure 10.32 AI-based Digital Pathology Market for Other Indications, till 2035 (USD Million)
• Figure 10.33 AI-based Digital Pathology Market: Distribution by Geography, Current Year and 2035
• Figure 10.34 AI-based Digital Pathology Market in North America, till 2035 (USD Million)
• Figure 10.35 AI-based Digital Pathology Market in the US, till 2035 (USD Million)
• Figure 10.36 AI-based Digital Pathology Market in Canada, till 2035 (USD Million)
• Figure 10.37 AI-based Digital Pathology Market in Europe, till 2035 (USD Million)
• Figure 10.38 AI-based Digital Pathology Market in UK, till 2035 (USD Million)
• Figure 10.39 AI-based Digital Pathology Market in the Germany, till 2035 (USD Million)
• Figure 10.40 AI-based Digital Pathology Market in Spain, till 2035 (USD Million)
• Figure 10.41 AI-based Digital Pathology Market in Italy, till 2035 (USD Million)
• Figure 10.42 AI-based Digital Pathology Market in France, till 2035 (USD Million)
• Figure 10.43 AI-based Digital Pathology Market in Asia, till 2035 (USD Million)
• Figure 10.44 AI-based Digital Pathology Market in China, till 2035 (USD Million)
• Figure 10.45 AI-based Digital Pathology Market in Japan, till 2035 (USD Million)
• Figure 10.46 AI-based Digital Pathology Market in South Korea, till 2035 (USD Million)
• Figure 10.47 AI-based Digital Pathology Market in Latin America, till 2035 (USD Million)
• Figure 10.48 AI-based Digital Pathology Market in Brazil, till 2035 (USD Million)
• Figure 10.49 AI-based Digital Pathology Market in MENA, till 2035 (USD Million)
• Figure 10.50 AI-based Digital Pathology Market in Saudi Arabia, till 2035 (USD Million)
• Figure 10.51 AI-based Digital Pathology Market in Rest of the World, till 2035 (USD Million)
• Figure 10.52 AI-based Digital Pathology Market in Australia, till 2035 (USD Million)
• Figure 11.1 Concluding Remarks: Market Landscape
• Figure 11.2 Concluding Remarks: Key Insights
• Figure 11.3 Concluding Remarks: Funding and Investments
• Figure 11.4 Concluding Remarks: Demand Analysis
• Figure 11.5 Concluding Remarks: Market Sizing and Opportunity Analysis